Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal SPARC peptide
- Development stage
- Preclinical
- Lead developer
- Wake Forest University School of Medicine
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides
- Administration
- Intravenous
01
Overview
Liposomal SPARC peptide is an experimental therapeutic formulation consisting of a peptide derived from the SPARC (Secreted Protein Acidic and Rich in Cysteine) protein encapsulated within a liposomal delivery system. The drug is designed to mimic a naturally occurring age-associated protective mechanism in the brain. Research indicates that aging activates MT1G/NFκB signaling in reactive astrocytes, leading to the secretion of SPARC, which inhibits brain metastasis. The liposomal SPARC peptide acts by targeting and inhibiting Integrin Beta 1 (ITGB1) signaling in tumor cells, thereby suppressing tumor growth and limiting the colonization of the brain by lung cancer cells. This targeted therapy is specifically being investigated to prevent or treat brain metastasis in younger lung cancer patients who lack the elevated SPARC levels typically found in older populations.
- Other names
- liposome-encapsulated SPARC peptide
02
Targets
ITGB1 (Integrin beta-1)
Beyond the preview
Go deeper on liposomal SPARC peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal SPARC peptide.